Clinical Trials Sponsored by Stellar Pharmaceuticals

Total 20906 results

OSI Pharmaceuticals

Completed

Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer

Advanced Pancreatic Cancer

United States
OSI Pharmaceuticals

Completed

Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer

Advanced Non Small Cell Lung Cancer | Failed Prior Chemotherapy

United States
Astellas Pharma Inc
OSI Pharmaceuticals

Completed

A Phase III Study of the Efficacy of Taxotere/Aptosyn Versus Taxotere/Placebo in Non-Small Cell Lung Cancer Patients

Non-Small Cell Lung Cancer

United States
Astellas Pharma Inc
OSI Pharmaceuticals

Completed

Phase II Study of Taxotere in Combination With Exisulind in Non-Small Cell Lung Cancer (NSCLC) Patients

NSCLC

United States
Astellas Pharma Inc
OSI Pharmaceuticals

Completed

A Pilot Study of OSI-461 in Patients With Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

United States
Astellas Pharma Inc
OSI Pharmaceuticals

Completed

Phase I Study of OSI-930 and Erlotinib in Cancer Tumors

Advanced Solid Tumors

United States, United Kingdom
Dr. J. Curtis Nickel
Stellar Pharmaceuticals

Completed

URACYST® For the Treatment of GAG Deficient Interstitial Cystitis

Interstitial Cystitis | Painful Bladder Syndrome

Canada
OSI Pharmaceuticals

Terminated

Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma (PETEY)

Recurrent or Refractory Pediatric Ependymoma

United States, Canada, United Kingdom
OSI Pharmaceuticals

Terminated

Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205

Ependymoma

United States, Canada, United Kingdom
OSI Pharmaceuticals

Completed

A Pharmacokinetic Study of Erlotinib in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic Function

Advanced Solid Tumors

United States, United Kingdom
OSI Pharmaceuticals

Completed

A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors (RADIANT)

Non-small Cell Lung Cancer

United States, Hungary, Spain, Taiwan, Korea, Republic of, Italy, United Kingdom, Canada, Australia, Belgium, Germany, Austria, Poland, Romania, Argentina, France, Czech Republic, Greece, Russian Federation
OSI Pharmaceuticals

Completed

Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2

Non-Small Cell Lung Cancer

United States
OSI Pharmaceuticals

Completed

Erlotinib (Tarceva) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLC

Carcinoma, Non-Small-Cell Lung

United States, United Kingdom
OSI Pharmaceuticals

Completed

A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva in Patients With Stage IIIB/IV Non-small Cell Lung Cancer Who Continue to Smoke After Failure of One or Two Prior Chemotherapy Regimens

NSCLC

United Kingdom, United States
Astellas Pharma Inc
OSI Pharmaceuticals

Completed

Efficacy and Safety Study of OSI-211 (Liposomal Lurtotecan) to Treat Recurrent Small Cell Lung Cancer

SCLC | Carcinoma, Small Cell

United Kingdom, United States
Astellas Pharma Inc
OSI Pharmaceuticals

Completed

Study of OSI-211 vs. Topotecan in Patients With Relapsed Epithelial Ovarian Cancer

Ovarian Neoplasms

United Kingdom, United States
Astellas Pharma Inc
OSI Pharmaceuticals

Completed

Study of CP-461 in Patients With Advanced Renal Cell Cancer

Renal Cell Carcinoma

United States
Astellas Pharma Inc
OSI Pharmaceuticals

Completed

Phase 1 Study of OSI-930 in Cancer Patients

Advanced Solid Tumors

United States, United Kingdom
Ganymed Pharmaceuticals GmbH

Completed

Phase 1 Trial of IMAB027 in Patients With Recurrent Advanced Ovarian Cancer (OVAR) (OVAR)

Ovarian Cancer

Belgium, Germany
Astellas Pharma Inc
Basilea Pharmaceutica

Completed

Drug Interaction Study of Isavuconazole and Midazolam

Healthy Volunteers | Pharmacokinetics of Isavuconazole | Pharmacokinetics of Midazolam

United States
Ganymed Pharmaceuticals GmbH

Completed

Safety and Tolerability Study of Claudiximab in Patients With Advanced Gastroesophageal Cancer

Solid Tumors

Germany, Latvia
AVEO Pharmaceuticals, Inc.
Astellas Pharma Inc

Terminated

A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With Metastatic RCC (TAURUS)

Metastatic Renal Cell Carcinoma

France, United Kingdom, Germany, Spain, Belgium, United States, Italy
AVEO Pharmaceuticals, Inc.
Astellas Pharma Inc

Terminated

Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (BATON-BC)

Triple Negative Breast Cancer

Germany, Taiwan, Spain, Ukraine, Australia, Korea, Republic of, Canada, United States, Italy, Bahamas
Ganymed Pharmaceuticals GmbH

Completed

Efficacy and Safety Study of Multiple Doses of IMAB362 in Patients With Advanced Gastroesophageal Cancer

Solid Tumors

Germany, Switzerland, Latvia, Bulgaria, Lithuania
Cumberland Pharmaceuticals
Astellas Pharma US, Inc.

Completed

Study of IV YM087 to Assess Efficacy and Safety in Patients With Euvolemic or Hypervolemic Hyponatremia

Hyponatremia

United States, South Africa, Israel, Canada
Astellas Pharma Inc
Basilea Pharmaceutica

Completed

Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections

Mycoses | Candidemia | Candidiasis, Invasive

Philippines, New Zealand, United States, Spain, Belgium, Canada, Israel, Malaysia, Mexico, Italy, Australia, Germany, Singapore, Hungary, Brazil, Thailand, China, India, Argentina, France, Russian Federation, Chile, Lebanon, South Africa and more
Astellas Pharma Europe B.V.
Cubist Pharmaceuticals LLC

Completed

A Study to Assess the Effects of Multiple Doses of Fidaxomicin on a Single Dose of Rosuvastatin in Healthy Male Subjects

Healthy Subjects | Drug-Drug Interaction (DDI) | Intestinal Absorption | Pharmacokinetics of Rosuvastatin | Pharmacokinetics of Fidaxomicin

Germany
Astellas Pharma Europe Ltd.
Cubist Pharmaceuticals LLC

Terminated

A Post-marketing, Blinded Study to Investigate How Effective Fidaxomicin is Compared to Vancomycin in the Sustained Cure of Clostridium Difficile Infection in Adults That Are Receiving Therapy to Suppress the Immune System (FREEDOM)

Clostridium Difficile

Spain, France, Germany, Greece, Denmark, Austria, Poland
Novartis Pharmaceuticals
Chugai Pharmaceutical

Completed

Study of Safety and Efficacy of Letrozole Monotherapy as Second-line Endocrine Therapy in Postmenopausal Patients With Advanced Breast Cancer Who Received Previous Anti-estrogen Treatment

Postmenopausal Women With Advanced Breast Cancer

Japan
Novartis Pharmaceuticals
Chugai Pharmaceutical

Completed

Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer

Postmenopausal Women With Advanced Breast Cancer

Japan
Astellas Pharma Global Development, Inc.
Cubist Pharmaceuticals LLC

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Fidaxomicin in Healthy Male Japanese and Caucasian Subjects

Healthy Subjects | Pharmacokinetics of Fidaxomicin

United States
Astellas Pharma Inc
OSI Pharmaceuticals; Cell Pathways

Terminated

CP-461 in the Treatment of Patients With Advanced Melanoma

Malignant Melanoma

United States
Novartis Pharmaceuticals
Chugai Pharmaceutical

Completed

Study of High-dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer

Postmenopausal Women With Advanced Breast Cancer

Japan
Astellas Pharma Inc
OSI Pharmaceuticals; Cell Pathways

Completed

CP-461 for the Treatment of Crohn's Disease

Crohn's Disease

United States
Astellas Pharma Inc
OSI Pharmaceuticals; Cell Pathways

Completed

Study Using CP-461 to Treat Advanced Prostate Cancer

Prostate Cancer

United States
Astellas Pharma Inc
OSI Pharmaceuticals; Cell Pathways

Completed

Dose-Escalating and Safety Study of CP-461 in Patients With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States
Ono Pharmaceutical Co. Ltd
Astellas Pharma Inc

Completed

Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan

Involutional Osteoporosis

Japan
Astellas Pharma Inc
Ono Pharmaceutical Co. Ltd

Completed

ONO-5920/YM529 Confirmatory Study in Involutional Osteoporosis Patients

Osteoporosis | Bone Loss, Age-Related

Japan
Ono Pharmaceutical Co. Ltd
Astellas Pharma Inc

Completed

Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan

Involutional Osteoporosis
Novartis Pharmaceuticals
Pharmaceutical Research Associates

Withdrawn

Pharmacokinetics Study of TNO155 in Participants With Mild, Moderate, or Severe Renal Impairment Compared to Matched Healthy Participants

Renal Impairment
Novartis Pharmaceuticals
Pharmaceutical Research Associates

Withdrawn

Pharmacokinetics of TNO155 in Participants With Mild, Moderate, or Severe Hepatic Impairment Compared to Matched Healthy Participants

Hepatic Impairment
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Completed

Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip (FACT OA2)

Osteoarthritis, Knee | Osteoarthritis, Hip

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

A Study of EDP-514 in Patients With Chronic Hepatitis B Virus Infection Who Are Not Currently on Treatment

Chronic HBV Infection

Hong Kong, Taiwan
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Terminated

Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee (FACT CLBP 1)

Osteoarthritis | Chronic Low Back Pain

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy Subjects

RSV Infection

United States
Melior Pharmaceuticals
Bukwang Pharmaceutical, Co., Ltd.

Completed

Adult Subjects With Uncontrolled Type 2 Diabetes

Type 2 Diabetes

United States
Tibotec Pharmaceuticals, Ireland
Tibotec Pharmaceutical Limited

Completed

A Safety Study to Evaluate the Antiviral Activity of Darunavir in Combination With Ritonavir in HIV 1 Infected Children

Human Immunodeficiency Virus 1

South Africa, Argentina, Brazil, India, Kenya
Vertex Pharmaceuticals Incorporated
Tibotec Pharmaceutical Limited

Completed

A Study to Examine the Effects of Telaprevir on the Pharmacokinetics of Cyclosporine and Tacrolimus in Healthy Adults

Hepatitis C

United States
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Terminated

Study to Evaluate Arthroplasty Specimens for Osteoarthritis of the Knee and Hip

Osteoarthritis, Knee | Osteoarthritis, Hip

United States, Poland, United Kingdom
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects

RSV Infection

United States

Clinical Trials Sponsored by Stellar Pharmaceuticals

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Chile

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations